Early effect of nasal salmon calcitonin on the bone marker Crosslaps

Abstract

The aim of this study was to investigate the early effect of nasal salmon calcitonin on a bone-resorption marker, "Crosslaps", in postmenopausal osteoporotic women. In this randomized, single-blind and placebo-controlled study we included 78 postmenopausal women with osteoporosis, between 45 and 65 years of age, with at least 5 years duration of menopause. Patients were randomly divided into two groups, the treatment and the placebo groups. Patients in the treatment group were given 100 IU day(-1) nasal salmon calcitonin, 1,000 mg day(-1) elemental calcium, and 400 IU day(-1) vitamin D. Patients in the placebo group took only 1,000 mg day(-1) elemental calcium, and 400 IU day(-1) vitamin D. The outcome measurements were urinary deoxypyridinoline, serum alkaline phosphatase, osteocalcin, and Crosslaps. The treatment group consisted of 39 patients whose mean age was 60.4 +/- 6 years and the placebo group included 39 patients with a mean age of 60.5 +/- 4.9 years. There was no significant difference between two groups in terms of demographic characteristics. The results of bone marker measurements were analyzed statistically. Crosslaps levels in the treatment group were significantly lower (P < 0.05) than in the placebo group. Other bone marker levels at the end of the study were not significantly lower (P > 0.05) than those at baseline in both treatment and placebo groups, however. Salmon calcitonin affects bone turnover within a few months and bone-resorption markers such as Crosslaps can be used to monitor the effect of nasal salmon calcitonin in the early phase of treatment for postmenopausal osteoporosis.

Crosslaps sériques chez l'enfant: valeurs de référence et intérêt en pathologie

“…La modification des taux de crosslaps sériques, après seulement un mois de traitement, était même significativement corrélée aux changements de densité miné-rale osseuse à un an de traitement. Dans le même cadre, les crosslaps sont également un marqueur d'efficacité du traitement par calcitonine de saumon par voie nasale [13]. Ils reflètent également l'efficacité du traitement classique de l'ostéoporose et de l'ostéopénie de l'enfant [3] et du traitement par biphosphonates du SAPHO syndrome [21], et de l'hyperphosphatasémie chronique idiopathique [22].…”

Effect of Nasal Calcitonin on the Health-Related Quality of Life in Postmenopause Women Affected With Low Bone Density

“…Bone micro-architecture remodeling is continuous and natural process containing bone resorption and new bone formation. These regular processes also control the calcium homeostasis, and replacement of bone tissue affected by microfractures ( 2 ). Therefore, OPS can cause several major skeletal problems, such as pathologic fracture and thereby put at risk the general health.…”

“…Low Bone Density (LBD) is one of the most challenging worldwide therapeutic problems, particularly in the developed country ( 2 , 4 ). Different therapeutic agents have been recommended for OPS and OPN that they purpose to prevent the disease progression or reduce the risk of fractures.…”

Low-Level Laser Therapy and Calcitonin in Bone Repair: Densitometric Analysis

“…During the remodeling process, several cytokines, peptides, and growth factors are released locally. Bone-formation markers include serum osteocalcin, bonespecific alkaline phosphatase, and procollagen I carboxyterminal propeptide [4].…”